The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease
Open accessAbstract
Alzheimer's disease (AD) is pathologically defined by extracellular accumulation of amyloid-β (Aβ) peptides generated by the cleavage of amyloid precursor protein (APP), strings of hyperphosphorylated Tau proteins accumulating inside neurons known as neurofibrillary tangles (NFTs) and neuronal loss. The association between the two hallmarks and cognitive decline has been known since the beginning of the 20th century when the first description of the disease was carried out by Alois Alzheimer. Today, more than 40 million people worldwide are affected by AD that represents the most common cause of dementia and there is still no effective treatment available to cure the disease. In general, the aggregation of Aβ is considered an essential trigger in AD pathogenesis that gives rise to NFTs, neuronal dysfunction and dementia. During the process leading to AD, tau and Aβ first misfold and form aggregates in one brain region, from where they spread to interconnected areas of the brain thereby inducing its gradual morphological and functional deterioration. In this mini-review article, we present an overview of the current literature on the spreading mechanisms of Aβ and tau pathology in AD since a more profound understanding is necessary to design therapeutic approaches aimed at preventing or halting disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Although the ultimate proof for a causal relationship between fibrillar aggregates and neurodegenerative diseases has not been delivered yet, the ‘‘amyloid cascade hypothesis’’ is still the most prevalent theory (Hardy and Higgins, 1992; Hardy and Selkoe, 2002) with the constrain that Aβ alone is most likely not able…”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“…et al., 2008, 2009; Shah et al., 2010), different studies have identified soluble oligomeric Aβ species as the toxic drivers responsible for synaptic dysfunction, in particular in the early stage of the disease (Lambert et al., 1998; Shankar et al., 2008; Koffie et al., 2009; Forloni et al., 2016).”
BackgroundPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061 · cited 1×
“the brains of individuals with AD (Fitzpatrick et al., 2017; Falcon et al., 2018).”
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“…strategies that aim at reducing tau levels in mice that co-express Aβ and human tau prevented neuronal loss (DeVos et al., 2018) as well as excitotoxin-induced neuronal dysfunctions (Roberson et al., 2007) and ameliorated the behavioral and gene expression phenotypes (Pickett et al., 2019).”
Background
Cited by
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Houldsworth, A. (2023) · Brain Communications · doi:10.1093/braincomms/fcad356 · Cited by 417
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology
Zou, P., Wu, C., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00385-7 · Cited by 97
Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases
Meldolesi, J. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00040-5 · Cited by 47
Microglia degrade Alzheimer’s amyloid-beta deposits extracellularly via digestive exophagy
Jacquet, R. G., González Ibáñez, F., Picard, K., Funes, L., Khakpour, M., Gouras, G. K., Tremblay, M.-È., Maxfield, F. R., & Solé-Domènech, S. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115052 · Cited by 42
Marcatti, M., Fracassi, A., Montalbano, M., Natarajan, C., Krishnan, B., Kayed, R., & Taglialatela, G. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04255-9 · Cited by 38
The emerging double-edged sword role of exosomes in Alzheimer’s disease
Liang, T., Wu, Z., Li, J., Wu, S., Shi, W., & Wang, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1209115 · Cited by 37
Integrative network analysis reveals novel moderators of Aβ-Tau interaction in Alzheimer's disease
Kitani, A., Matsui, Y., & Initiative, F. T. A. D. N. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01705-x · Cited by 6
“Alzheimer’s disease (AD) is the most common form of dementia, characterized by extracellular amyloid-beta (Aβ) plaques and intracellular tau protein tangles, which are believed to be central to its pathology [1–3].”
Desale, S. H., Doshi, P. P., Khutale, A. A., & Suresh, S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103379
Metadata
- Authors
- d‘Errico, P., & Meyer-Luehmann, M.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2020-08-27
- Volume
- 12
- Pages
- 265-265
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W3081437647
- Cited by
- 175
- References
- 78
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.